ADP355

Evidence in perspective

The liver-injury paper’s correction changes D-amino-acid positions in the stated sequence. That identity detail must be retained before interpreting activity; animal fibrosis and cell results remain separate from clinical treatment evidence.

Who was studied

Cell models; separate studies examine chemically induced injury in animals.

What the sources found

ADP355 inhibited proliferation in selected cancer cell lines and renal myofibroblast differentiation in vitro.

Cell models; separate studies examine chemically induced injury in animals.

Source · Results / abstract

Regulatory scope

No jurisdiction-specific marketing authorization has been verified in this snapshot; study publication is not regulatory approval.

What remains unknown

These findings do not establish human efficacy, long-term safety, or equivalence to products sold under this name. This is a focused source snapshot, not an exhaustive clinical review. The 2016 correction changes the reported ADP355 stereochemical sequence in Methods; matching sequence and D-amino-acid positions matters. The correction was read in full.

How it works

ADP355 is an experimental peptide agonist of adiponectin receptors.

Read the study-specific findings and limitations in Medical. Mechanistic activity does not establish a treatment benefit.

Preclinical research

The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.

Understanding the evidence

Reported adverse effects

• The cited evidence does not establish comprehensive human adverse-event rates.